Back to search

University of Nevada, Reno

Production and purification of recombinant human laminin-111 for pre-clinical testing in a murine model of laminin-α2 deficient congenital muscular dystrophy

Abstract

dc:description.abstract

Laminin α2-deficient congenital muscular dystrophy (LAMA2-CMD) is a fatal genetic neuromuscular disease that currently has no cure. Patients with LAMA2-CMD suffer from muscle wasting, respiratory issues, and neurological effects until eventual death at a premature age due to loss of the adult isoforms of laminin, laminin 211/221, from the basal lamina. Previous research in the Burkin lab has shown effective treatment of the dyW mouse model of LAMA2-CMD through successful substitution of these adult laminin isoforms using injections of the mouse embryonic laminin isoform, laminin-111. What has not been explored in these studies is whether the dyW mouse model could also be successfully treated with a recombinant human form of laminin-111, as human patients would require treatment with the human isoform. To determine whether human laminin-111 could be used to treat the LAMA2-CMD mouse model, recombinant human laminin-111 (rhLAM-111) was produced in Chinese hamster ovary (CHO) cells for extraction and purification to be later used for pre-clinical testing in the dyW mouse model. Our results show rhLAM-111 purification was unsuccessful, indicating heparin affinity chromatography, gel filtration, immobilized metal affinity chromatography (IMAC), and phosphocellulose columns were not efficient or optimized for successful purification and concentration of rhLAM-111. These results indicate the need for a different purification strategy in order to produce enough pure laminin for further research examining the effectiveness of rhLAM-111 in treating the dyW mouse model of LAMA2-CMD

Degree

thesis:*
Name thesis:degree_name
Nutrition
Level thesis:degree_level
Honors Thesis
Department thesis:degree_department
Pharmacology
Grantor
University of Nevada, Reno
Year dc:date.issued
2017

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Smith, Deryan
Advisors dc:contributor.advisor
  • Burkin, Dean J.
  • Brewer, Paul

Rights

dc:rights
Statement dc:rights
  • Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 United States
  • Author(s)
Language dc:language.iso
en_US, English

Identifiers

dc:identifier.*
Handle dc:identifier.uri
http://hdl.handle.net/11714/1911

Chain of custody

source
Harvested from
University of Nevada - Reno
Base URL
scholarwolf.unr.edu/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Smith, Deryan. Production and purification of recombinant human laminin-111 for pre-clinical testing in a murine model of laminin-α2 deficient congenital muscular dystrophy. Honors Thesis thesis, University of Nevada, Reno, 2017. http://hdl.handle.net/11714/1911